$3 Billion is the total value of Perceptive Advisors's 97 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 33.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Buy | AMICUS THERAPEUTICS INC | $336,745,870 | -3.1% | 27,692,917 | +0.1% | 11.23% | +11.7% |
| CERE | CEREVEL THERAPEUTICS HLDNG I | $220,229,445 | -31.3% | 10,088,385 | 0.0% | 7.35% | -20.9% | |
| IMVT | Buy | IMMUNOVANT INC | $146,445,987 | +205.9% | 3,814,691 | +51.1% | 4.88% | +252.5% |
| Sell | ARCELLX INC | $142,299,291 | +12.0% | 3,965,978 | -1.3% | 4.75% | +29.1% | |
| Buy | NUVALENT INC | $113,244,842 | +22.4% | 2,463,451 | +12.2% | 3.78% | +41.0% | |
| Buy | SOLENO THERAPEUTICS INC | $90,729,734 | +857.9% | 3,074,542 | +39.3% | 3.03% | +1004.4% | |
| LIANBIOsponsored ads | $85,762,091 | -34.6% | 57,558,451 | 0.0% | 2.86% | -24.7% | ||
| AKRO | Sell | AKERO THERAPEUTICS INC | $81,910,517 | -9.6% | 1,619,425 | -16.6% | 2.73% | +4.2% |
| INBX | Buy | INHIBRX INC | $78,099,508 | -17.0% | 4,256,104 | +17.4% | 2.60% | -4.3% |
| ALDX | ALDEYRA THERAPEUTICS INC | $75,818,568 | -20.4% | 11,350,085 | 0.0% | 2.53% | -8.2% | |
| ARGX | Buy | ARGENX SEsponsored adr | $74,039,478 | +175.3% | 150,600 | +118.3% | 2.47% | +217.5% |
| PCVX | Sell | VAXCYTE INC | $68,453,446 | -15.1% | 1,342,751 | -16.8% | 2.28% | -2.1% |
| VRNA | Sell | VERONA PHARMA PLCsponsored ads | $65,317,311 | -29.7% | 4,007,197 | -8.9% | 2.18% | -19.0% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $60,283,978 | +47.5% | 4,043,191 | +8.3% | 2.01% | +70.0% |
| MGTX | MEIRAGTX HLDGS PLC | $55,635,715 | -26.9% | 11,331,103 | 0.0% | 1.86% | -15.8% | |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $54,431,367 | -44.9% | 11,962,938 | -14.8% | 1.82% | -36.5% |
| LYRA | LYRA THERAPEUTICS INC | $49,882,067 | -4.9% | 12,757,562 | 0.0% | 1.66% | +9.6% | |
| Sell | AMYLYX PHARMACEUTICALS INC | $49,233,265 | -53.2% | 2,688,873 | -44.8% | 1.64% | -46.0% | |
| BBIO | BRIDGEBIO PHARMA | $46,119,363 | +53.3% | 1,748,933 | 0.0% | 1.54% | +76.6% | |
| MDT | Buy | MEDTRONIC PLC | $45,997,320 | +11.8% | 587,000 | +25.7% | 1.53% | +28.8% |
| Buy | ROIVANT SCIENCES LTD | $44,611,246 | +41.3% | 3,819,456 | +22.0% | 1.49% | +62.8% | |
| Buy | DISC MEDICINE INC | $42,077,214 | +27.6% | 895,641 | +20.6% | 1.40% | +47.0% | |
| IMTX | IMMATICS N.V | $40,431,570 | +0.3% | 3,491,500 | 0.0% | 1.35% | +15.7% | |
| New | APOGEE THERAPEUTICS INC | $38,934,291 | – | 1,827,901 | +100.0% | 1.30% | – | |
| CRNX | Sell | CRINETICS PHARMACEUTICALS IN | $37,583,389 | +7.1% | 1,263,732 | -35.1% | 1.25% | +23.5% |
| RVMD | New | REVOLUTION MEDICINES INC | $36,587,286 | – | 1,321,795 | +100.0% | 1.22% | – |
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $35,152,017 | -12.8% | 1,520,416 | -1.1% | 1.17% | +0.5% |
| AXSM | Buy | AXSOME THERAPEUTICS INC | $33,662,449 | +72.5% | 481,649 | +77.4% | 1.12% | +98.8% |
| HRMY | Buy | HARMONY BIOSCIENCES HLDGS IN | $32,648,948 | +4.1% | 996,306 | +11.8% | 1.09% | +19.9% |
| RAPT | Sell | RAPT THERAPEUTICS INC | $31,921,336 | -25.4% | 1,920,658 | -16.1% | 1.06% | -14.0% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $31,092,899 | +33.9% | 1,517,467 | +29.9% | 1.04% | +54.3% |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $28,791,237 | -18.3% | 9,111,151 | 0.0% | 0.96% | -6.0% | |
| ACRIVON THERAPEUTICS INC | $28,755,122 | -26.2% | 3,007,858 | 0.0% | 0.96% | -15.0% | ||
| New | TANGO THERAPEUTICS INC | $27,237,580 | – | 2,418,968 | +100.0% | 0.91% | – | |
| ADMA | Sell | ADMA BIOLOGICS INC | $25,003,862 | -43.1% | 6,984,319 | -41.3% | 0.83% | -34.4% |
| TMCI | Sell | TREACE MED CONCEPTS INC | $24,044,527 | -57.6% | 1,834,060 | -17.3% | 0.80% | -51.2% |
| TARS | TARSUS PHARMACEUTICALS INC | $23,037,312 | -1.7% | 1,296,416 | 0.0% | 0.77% | +13.3% | |
| COGT | Sell | COGENT BIOSCIENCES INC | $22,517,333 | -28.5% | 2,309,470 | -13.2% | 0.75% | -17.6% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $22,149,318 | +138.6% | 182,720 | +125.4% | 0.74% | +174.7% |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $21,236,527 | +36.5% | 672,042 | +11.7% | 0.71% | +57.3% |
| Buy | ORCHESTRA BIOMED HLDGS INC | $21,207,816 | +47.6% | 2,432,089 | +18.5% | 0.71% | +70.0% | |
| XENE | Sell | XENON PHARMACEUTICALS INC | $21,093,800 | -55.2% | 617,500 | -49.5% | 0.70% | -48.3% |
| VRCA | VERRICA PHARMACEUTICALS INC | $19,576,448 | -32.7% | 5,038,983 | 0.0% | 0.65% | -22.4% | |
| Buy | BIOHAVEN LTD | $19,554,838 | +154.8% | 751,820 | +134.3% | 0.65% | +193.7% | |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $18,201,987 | -74.0% | 124,637 | -58.9% | 0.61% | -70.0% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $17,914,725 | +89.9% | 159,242 | +59.2% | 0.60% | +119.0% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $17,585,274 | -56.7% | 1,054,273 | -28.3% | 0.59% | -50.0% |
| CABA | Sell | CABALETTA BIO INC | $17,236,513 | -13.6% | 1,132,491 | -26.7% | 0.58% | -0.3% |
| New | RAYZEBIO INC | $17,245,071 | – | 776,805 | +100.0% | 0.58% | – | |
| ASTRIA THERAPEUTICS INC | $16,333,387 | -10.4% | 2,189,462 | 0.0% | 0.54% | +3.2% | ||
| RLAY | RELAY THERAPEUTICS INC | $16,341,445 | -33.0% | 1,943,097 | 0.0% | 0.54% | -22.8% | |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $15,511,885 | -63.3% | 1,011,205 | -43.1% | 0.52% | -57.7% |
| CRY | ARTIVION INC | $14,119,296 | -11.8% | 931,352 | 0.0% | 0.47% | +1.7% | |
| ESTA | Sell | ESTABLISHMENT LABS HLDGS INC | $13,625,905 | -53.3% | 277,683 | -34.7% | 0.46% | -46.1% |
| EOLS | New | EVOLUS INC | $13,580,221 | – | 1,485,801 | +100.0% | 0.45% | – |
| TCMD | Buy | TACTILE SYS TECHNOLOGY INC | $9,935,584 | -33.8% | 707,159 | +17.4% | 0.33% | -23.9% |
| BMEA | BIOMEA FUSION | $9,858,228 | -37.3% | 716,441 | 0.0% | 0.33% | -27.7% | |
| ATHA | ATHIRA PHARMA INC | $9,690,501 | -31.5% | 4,797,278 | 0.0% | 0.32% | -21.2% | |
| NTRA | Sell | NATERA INC | $9,654,377 | -51.0% | 218,178 | -46.2% | 0.32% | -43.6% |
| Sell | ZYMEWORKS INC | $9,168,420 | -56.1% | 1,446,123 | -40.1% | 0.31% | -49.3% | |
| SOLID BIOSCIENCES INC | $8,809,751 | -51.9% | 3,495,933 | 0.0% | 0.29% | -44.5% | ||
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $8,730,482 | – | 380,828 | +100.0% | 0.29% | – |
| CMAX | Buy | CAREMAX INC | $8,105,940 | -31.7% | 3,823,557 | +0.2% | 0.27% | -21.5% |
| PRTA | Sell | PROTHENA CORP PLC | $7,990,924 | -36.6% | 165,615 | -10.3% | 0.27% | -26.8% |
| OM | Sell | OUTSET MED INC | $7,202,310 | -63.5% | 661,977 | -26.6% | 0.24% | -58.0% |
| FUSN | FUSION PHARMACEUTICALS INC | $7,153,627 | -44.3% | 2,751,395 | 0.0% | 0.24% | -35.8% | |
| LANDOS BIOPHARMA INC | $5,769,525 | -7.8% | 1,486,991 | 0.0% | 0.19% | +6.1% | ||
| AKRO | New | AKERO THERAPEUTICS INCcall | $5,460,000 | – | 800,000 | +100.0% | 0.18% | – |
| TERN | New | TERNS PHARMACEUTICALS INC | $5,407,250 | – | 1,075,000 | +100.0% | 0.18% | – |
| TYRA BIOSCIENCES INC | $4,957,200 | -19.1% | 360,000 | 0.0% | 0.16% | -6.8% | ||
| NBTX | Sell | NANOBIOTIXsponsored ads | $4,856,828 | -9.6% | 555,066 | -47.6% | 0.16% | +3.8% |
| AXGN | Sell | AXOGEN INC | $4,379,490 | -67.3% | 875,898 | -40.2% | 0.15% | -62.3% |
| ENVVENO MEDICAL CORPORATION | $4,212,905 | +75.0% | 781,615 | 0.0% | 0.14% | +101.4% | ||
| XFOR | X4 PHARMACEUTICALS INC | $3,864,545 | -43.8% | 3,545,454 | 0.0% | 0.13% | -35.2% | |
| NVAX | New | NOVAVAX INCput | $3,772,520 | – | 1,300,000 | +100.0% | 0.13% | – |
| SOMALOGIC INC | $3,585,000 | +3.5% | 1,500,000 | 0.0% | 0.12% | +20.0% | ||
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $3,576,000 | +156.5% | 400,000 | +340.8% | 0.12% | +197.5% |
| SRPT | New | SAREPTA THERAPEUTICS INCcall | $3,130,000 | – | 100,000 | +100.0% | 0.10% | – |
| PNT | Buy | POINT BIOPHARMA GLOBAL INCput | $2,630,000 | +289.6% | 800,000 | +60.0% | 0.09% | +340.0% |
| ARQT | ARCUTIS BIOTHERAPEUTICS INCput | $2,622,500 | +85.0% | 300,000 | 0.0% | 0.09% | +112.2% | |
| EYPT | New | EYEPOINT PHARMACEUTICALS INCput | $2,512,500 | – | 750,000 | +100.0% | 0.08% | – |
| KRON | KRONOS BIO INC | $2,278,568 | -24.4% | 1,752,745 | 0.0% | 0.08% | -12.6% | |
| FBRX | New | FORTE BIOSCIENCES INC | $2,161,667 | – | 3,265,359 | +100.0% | 0.07% | – |
| ACELYRIN INC | $2,034,000 | -51.3% | 200,000 | 0.0% | 0.07% | -43.8% | ||
| ETNB | New | 89BIO INCcall | $1,620,000 | – | 400,000 | +100.0% | 0.05% | – |
| ACRS | New | ACLARIS THERAPEUTICS INCput | $1,450,000 | – | 500,000 | +100.0% | 0.05% | – |
| New | AEGLEA BIOTHERAPEUTICS INC | $993,671 | – | 81,116 | +100.0% | 0.03% | – | |
| VBI VACCINES INC CDA | $925,507 | -79.6% | 1,381,355 | 0.0% | 0.03% | -76.5% | ||
| OMIC | SINGULAR GENOMICS SYSTEMS IN | $900,385 | -54.1% | 2,363,214 | 0.0% | 0.03% | -47.4% | |
| VERU | Buy | VERU INC | $783,622 | +632.7% | 1,089,878 | +1112.6% | 0.03% | +766.7% |
| VKTX | New | VIKING THERAPEUTICS INCcall | $240,000 | – | 300,000 | +100.0% | 0.01% | – |
| Sell | LEAP THERAPEUTICS INC | $62,059 | -96.6% | 44,971 | -92.3% | 0.00% | -96.2% | |
| APLS | New | APELLIS PHARMACEUTICALS INCput | $72,500 | – | 100,000 | +100.0% | 0.00% | – |
| MOTUS GI HLDGS INC | $40,512 | -32.8% | 90,027 | 0.0% | 0.00% | -50.0% | ||
| BTAI | Exit | BIOXCEL THERAPEUTICS INCcall | $0 | – | -439,500 | -100.0% | 0.00% | – |
| EQRX INC*w exp 12/17/202 | $10,000 | -76.5% | 250,000 | 0.0% | 0.00% | -100.0% | ||
| SURROZEN INC*w exp 08/01/203 | $6,667 | -33.3% | 166,666 | 0.0% | 0.00% | – | ||
| CMAXW | CAREMAX INC*w exp 06/08/202 | $11,250 | -51.9% | 60,000 | 0.0% | 0.00% | -100.0% | |
| XBI | Exit | SPDR SER TRput | $0 | – | -150,000 | -100.0% | -0.00% | – |
| VRNA | Exit | VERONA PHARMA PLCcall | $0 | – | -500,000 | -100.0% | -0.02% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INCcall | $0 | – | -200,000 | -100.0% | -0.02% | – |
| QTRX | Exit | QUANTERIX CORP | $0 | – | -130,000 | -100.0% | -0.08% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -168,000 | -100.0% | -0.19% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -441,147 | -100.0% | -0.21% | – |
| TERN | Exit | TERNS PHARMACEUTICALS INCput | $0 | – | -1,075,000 | -100.0% | -0.27% | – |
| ITCI | Exit | INTRA-CELLULAR THERAPIES INC | $0 | – | -245,800 | -100.0% | -0.45% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -263,207 | -100.0% | -0.66% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -719,103 | -100.0% | -0.75% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -145,000 | -100.0% | -0.79% | – |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -1,958,264 | -100.0% | -1.39% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -670,206 | -100.0% | -1.98% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -812,037 | -100.0% | -2.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
| SC 13D | 2024-03-20 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.